Photo of Dr. Jason S Buhrman

Jason S Buhrman

Graduate Research Assistant, Center for Clinical Translational Science
Predoctoral Fellow, Center for Clinical Translational Science


Research Interests: Drug delivery, Oncolytic virus, Cancer therapy

Selected Publications

  • Jaishankar DS, Buhrman JA, Valyi-Nagy T, Gemeinhart R, Shukla D. “Extended release of an anti-heparan sulfate peptide from a contact lens suppresses corneal Herpes Simplex Virus-1 (HSV-1) infection”. Investigative Ophthalmology and Visual Science. 2016;57(1):169-180. doi:10.1167/iovs.15-18365..
  • Rayahin JE, Buhrman JS, Zhang YJ, Koh TA, Gemeinhart R. “High and low molecular weight hyaluronic acid differentially influence macrophage activation”. ACS Biomaterials Science and Engineering. 2015;(1(7)):481-493. doi:10.1021/acsbiomaterials.5b00181.
  • Farrar CT, Buhrman JS, Liu G, Kleijn A, Lamfers ML, McMahon MT, Gilad AA, Fulci G. Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.. Radiology. 2015;275(3):746-54. doi:10.1148/radiol.14140251.
  • Rayahin JE, Buhrman JS, Gemeinhart RA. “Melittin-glutathione S-transferase fusion protein exhibits anti-inflammatory properties and minimal toxicity”. European Journal of Pharmaceutical Sciences. 2014;(65):112-121. doi:10.1016/j.ejps.2014.09.012.
  • Zhang YS, Köllmer MY, Buhrman JA, Tang M, Gemeinhart R. “Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential”. Peptides. 2014;(58(1)):83-90. doi:10.1016/j.peptides.2014.06.008.
  • Buhrman JS, Cook L, Rayahin JE, Federle M, Gemeinhart RA. “Proteolytically activated anti-bacterial hydrogel microspheres”. Journal of Controlled Release. 2013;(171(3)):2882-2895. doi:10.1016/j.jconrel.2013.06.023.
  • Buhrman JS, Rayahin JE, Cook L, Federle M, Gemeinhart RA. “Active, soluble recombinant melittin purified by extracting insoluble lysate of Escherichia coli without denaturation”. Biotechnology Progress. 2013;(29(5)):1150-1157. doi:10.1002/btpr.1784.
  • Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.. Neoplasia (New York, N.Y.). 2013;15(6):591-9.
  • Köllmer MS, Buhrman JA, Zhang Y, Gemeinhart R. “Markers are shared between adipogenic and osteogenic differentiated mesenchymal stem cells”. Journal of Developmental Biology and Tissue Engineering. 2013;(5(2)):18-25. doi:10.5897/JDBTE2013.0065.
  • Buhrman JS, Rayahin JE, Köllmer MA, Gemeinhart R. “In-house preparation of hydrogels for batch affinity purification of glutathione S-transferase tagged recombinant proteins”. BMC Biotechnology. 2012;(12):63. doi:10.1186/1472-6750-12-63.
  • Rayahin JE, Buhrman JS, Gemeinhart RA. “Hybrid nanocrystals: University of Kentucky US20060280680A1”. Expert Opinion on Therapeutic Patents. 2012;(22(3)):34134-8. doi:10.1517/13543776.2012.665877.
  • Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.. Molecular therapy : the journal of the American Society of Gene Therapy. 2012;20(1):37-45. doi:10.1038/mt.2011.187.
  • Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G. Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(13):4484-93. doi:10.1158/1078-0432.CCR-11-0575.
  • Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.. Gene therapy. 2010;17(6):805-10. doi:10.1038/gt.2010.20.
  • Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.. Cancer Gene Therapy. 2009;16(7):551-560.
  • Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.. Cancer gene therapy. 2009;16(7):551-60. doi:10.1038/cgt.2009.10.